References
- Wohlfarth A, Weinmann W. Bioanalysis of new designer drugs. Bioanalysis. 2010;2(5):965–979. doi: 10.4155/bio.10.32.
- Carroll FI, Lewin AH, Mascarella SW, et al. Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci. 2012;1248(1):18–38. doi: 10.1111/j.1749-6632.2011.06199.x.
- Smink BE, Ruiter B, Lusthof KJ, et al. Drug use and the severity of a traffic accident. Accid Anal Prev. 2005;37(3):427–433. doi: 10.1016/j.aap.2004.12.003.
- LeBeau MA. ANSI/ASB Standard 036 for method validation in forensic toxicology has replaced SWGTOX’s version. J Anal Toxicol. 2020;44(4):414–414. doi: 10.1093/jat/bkz115.
- Fagiola M, Hahn T, Avella J. Screening of novel psychoactive substances in postmortem matrices by liquid chromatography tandem mass spectrometry (LC–MS-MS). J Anal Toxicol. 2018;42(8):562–569. doi: 10.1093/jat/bky050.
- Gerostamoulos D, Elliott S, Walls HC, et al. To measure or not to measure? That is the NPS question. J Anal Toxicol. 2016;40(4):318–320. doi: 10.1093/jat/bkw013.
- Bareggi SR, Truci G, Leva S, et al. Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. Eur J Clin Pharmacol. 1988;34(1):109–112. doi: 10.1007/BF01061430.
- Adamowicz P, Malczyk A. Stsability of synthetic cathinones in blood and urine. For Sci Int. 2019;295:36–45.
- University of Maryland Center for Substance Abuse Research. DEA emerging threat reports. [cited 2023 Jul 1]. https://cesar.umd.edu/publications/dea-emerging-threat-reports.
- United Nations Office on Drugs and Crime (UNODC). [cited 2023 Sep 9]. https://dataunodc.un.org/dp-drug-seizures.
- Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal. 2014;6(7–8):614–632. doi: 10.1002/dta.1620.
- Prosser JM, Nelson LS. The toxicology of bath salts: A review of synthetic cathinones. J Med Toxicol. 2012;8(1):33–42. doi: 10.1007/s13181-011-0193-z.
- Høiseth G, Tuv SS, Karinen R. Blood concentrations of new designer benzodiazepines in forensic cases. Forensic Sci Int. 2016;268:35–38. doi: 10.1016/j.forsciint.2016.09.006.
- Specka M, Kuhlmann T, Sawazki J, et al. Prevalence of novel psychoactive substance (NPS) use in patients admitted to drug detoxification treatment. Front Psychiatry. 2020;11:569. doi: 10.3389/fpsyt.2020.00569.
- Mitchell-Mata C, Thomas B, Peterson B, et al. Two fatal intoxications involving 3-methoxyphencyclidine. J Anal Toxicol. 2017;41(6):503–507. doi: 10.1093/jat/bkx048.
- Wright TH. Suspected driving under the influence case involving mitragynine. J Anal Toxicol. 2018;42(7):e65–e68. doi: 10.1093/jat/bky028.
- Johansson A, Lindstedt D, Roman M, et al. A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP. Forensic Sci Int. 2017;275:76–82. doi: 10.1016/j.forsciint.2017.02.034.
- Knoy JL, Peterson BL, Couper FJ. Suspected impaired driving case involving α-pyrrolidinovalerophenone, methylone, and ethylone. J Anal Toxicol. 2014;38(8):615–617. doi: 10.1093/jat/bku073.
- Ellefsen KN, Taylor EA, Simmons P, et al. Multiple drug-toxicity involving novel psychoactive substances, 3-fluorophenmetrazine and U-47700. J Anal Toxicol. 2017;41(9):765–770. doi: 10.1093/jat/bkx060.
- Concheiro M, Chesser R, Pardi J, et al. Postmortem toxicology of new synthetic opioids. Front Pharmacol. 2018;9:1210. doi: 10.3389/fphar.2018.01210.
- Maskell PD, Elliott S, Desharnais B, et al. A model of evaluative opinion to encourage greater transparency and justification of interpretation in postmortem forensic toxicology. J Anal Toxicol. 2023;47(7):563–573.